Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14463493 | 0.89 | HPGD (0.40) | HPGDRAB9AALDH1A1GAALMNA | |
| SCHEMBL3581440 | 0.88 | HPGD (0.51) | HPGDRAB9AALDH1A1GAALMNA | |
| SCHEMBL13021530 | 0.86 | HPGD (0.49) | HPGDRAB9AALDH1A1GAALMNA | |
| SCHEMBL3584050 | 0.85 | HPGD (0.47) | HPGDRAB9AALDH1A1GAALMNA | |
| SCHEMBL14422472 | 0.81 | ALDH1A1 (0.43) | ALDH1A1GAALMNAMAPTKMT2A | |
| SCHEMBL2821089 | 0.81 | HPGD (0.62) | HPGDRAB9AALDH1A1GAALMNA | |
| SCHEMBL3937049 | 0.80 | POLB (0.42) | HPGDRAB9AALDH1A1GAALMNA | |
| SCHEMBL3941630 | 0.80 | SMN1; SMN2 (0.44) | ALDH1A1GAALMNAMAPTKMT2A | |
| SCHEMBL12390715 | 0.78 | HPGD (0.57) | HPGDRAB9AALDH1A1GAALMNA | |
| SCHEMBL2815972 | 0.78 | HPGD (0.57) | HPGDRAB9AALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507510-B2 | Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507510-B2 | Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-03-25 | — | — | US | disclosed |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-03-25 | — | — | US | disclosed |
| EP-1673352-B1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CD AND/OR VEGF-INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | BAYER SCHERING PHARMA AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| EP-1673352-B1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CD AND/OR VEGF-INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | BAYER SCHERING PHARMA AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7338958-B2 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-03-04 | — | — | US | disclosed |
| US-20070191393-A1 | Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007079982-A1 | (2 , 4 , 9-TRIAZA-1 (2 , 4 ) -PYRIMIDINA-3 ( 1 , 3 ) -BENZENACYCLONONAPHANE-3 4-YL) -SULFOXIMINE DERIVATIVES AS SELECTIVE AURORA KINASE INHIBITORS FOR THE TREATMENT OF CANCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | CDK2, CDK1, FLT1 | HPGD 835/4885RAB9A 3522/4885ALDH1A1 2681/4885 |
| US-20070191393-A1 | Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinases | CCNI, CDK2, CDK1 | HPGD 2250/4885RAB9A 4568/4885ALDH1A1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.